( The Food and Drug Administration. has g...)GlaxoSmithKline’s Epilepsy Drug given the Green Signal by FD,Health

The Food and Drug Administration. has given GlaxoSmithKline PLC's anti-seizure medicine to treat Primary Generalized Tonic-Clonic, or PGTC, the green signal.//

According to GlaxoSmithKline, the U.K. pharmaceutical company, the drug, Lamictal, has been approved to treat children age two and older, as well as adults.

PGTC seizures are said to be the most-serious and most-commonly occurring type of generalized seizures, seen in about 20% of patients with epilepsy.

Epilepsy is a recurrent, unprovoked seizure characterized by a change in sensation, awareness, or behavior which comes about by an electrical disturbance in the brain.

Lamictal has now received the fifth FDA approval. It been approved to treat partial and generalized seizures and as well as for use as maintenance therapy for adults with bipolar disorder.

The FDA's approval is said to have been based on a multicenter trial in pediatric and adult patients, which proved to be "highly effective" in reducing the frequency of generalized tonic-clonic seizures by 66%.


NLA
'"/>




Page: 1
Related medicine news :

1. GlaxoSmithKline’s Tykerb is to Be Started Earlier in Breast Cancer, Study Find
2. General Anesthesia Safe For Children On Ketogenic Diet Suffering From Epilepsy
3. Researchers Scale to assess the Severity of Epilepsy in Kids
4. Epilepsy can be predicted
5. Epilepsy Drugs Can Enhance Risk of Birth Defects
6. Epilepsy Drug Helps Diabetic Nerve Damage
7. Epilepsy Drug May Relieve Chronic Headaches
8. More Complications Seen In Women With Epilepsy
9. Epilepsy Drugs Found To Lead To Bone Loss
10. Another Use For Epilepsy Drugs
11. Epilepsy Patients Could Benefit From Pacemakers